Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis

International Journal of Molecular Sciences

Volumn 15, Issue 5, 2014, Pages 7651-7666

  Tsakovska, Ivanka ^a   Sharif, Merilin Al ^a   Alov, Petko ^a   Diukendjieva, Antonia ^a   Fioravanzo, Elena ^b   Cronin, Mark T D ^c   Pajeva, Ilza ^a  

^a INSTITUTE OF BIOPHYSICS AND BIOMEDICAL ENGINEERING   (Bulgaria)

^b S IN Soluzioni Informatiche   (Italy)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Liver steatosis; Mode of action; Molecular modelling; Pharmacophore; PPAR

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ISOTRETINOIN; LIGAND; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; ISOPROTEIN; PROTEIN BINDING;

ARTICLE; DRUG MECHANISM; DRUG SCREENING; FATTY LIVER; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN DATA BANK; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; X RAY ANALYSIS; AGONISTS; BINDING SITE; METABOLISM; MOLECULAR DYNAMICS; PATHOLOGY; PROTEIN DATABASE; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; DATABASES, PROTEIN; FATTY LIVER; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; PPAR GAMMA; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY;

EID: 84899784668     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15057651     Document Type: Article

References (44)

1. Cronin, M.T.D.; Richarz, A.N. Mode of action working group: Use of mode of action related to repeated dose systemic toxicity-A framework for capturing Information. In Towards the Replacement of in Vivo Repeated Dose Systemic Toxicity Testing; Gocht, T., Schwarz, M., Eds.; Imprimerie: Mouzet, France, 2012; Volume 2, pp. 284-289.
2. Organisation for Economic Co-operation and Development (OECD). Guidance Document on Developing and Assessing Adverse Outcome Pathways; Series on Testing and Assessment No. 184; OECD: Paris, France, 2013.
3. Fioravanzo, E.; Bassan, A.; Cronin, M.T.D.; Kovarich, S.; Manelfi, C.; Richarz, A.N.; Tsakovska, I.; Worth, A.P. Molecular modelling of LXR binding to evaluate the potential for liver steatosis. Toxicol. Lett. 2013, 221, S83.
4. Al Sharif, M.; Alov P, Cronin, M.; Fioravanzo, E.; Tsakovska, I.; Vitcheva, V.; Worth, A.; Yang, C.; Pajeva, I. Toward better understanding of liver steatosis MoA: Molecular modelling study of PPAR gamma receptor. Toxicol. Lett. 2013, 221, S85.
5. Al Sharif, M.; Alov, P.; Vitcheva, V.; Pajeva, I.; Tsakovska, I. Modes-of-action related to repeated dose toxicity: Tissue-specific biological roles of PPARγ ligand-dependent dysregulation in nonalcoholic fatty liver disease. PPAR Res. 2014, 2014, 432647:1-432647:13.
6. Landesmann, B.; Goumenou, M.; Munn, S.; Whelan, M. Description of Prototype Modes-Of-Action Related to Repeated dose Toxicity. Reference Report by the Joint Research Centre of the European Commission, Institute for Health and Consumer Protection, 2012, 40 Pages, EUR 25631 EN. Available online: http://publications.jrc.ec.europa.eu (accessed on 27 March 2014).
7. Costa, V.; Gallo, M.A.; Letizia, F.; Aprile, M.; Casamassimi, A.; Ciccodicola, A. PPARG: Gene expression regulation and next-generation sequencing for unsolved issues. PPAR Res. 2010, 2010, 409168:1-409168:17.
8. Kouskoumvekaki, I.; Petersen, R.K.; Fratev, F.; Taboureau, O.; Nielsen, T.E.; Oprea, T.I.; Sonne, S.B.; Flindt, E.N.; Jónsdóttir, S. Ó.; Kristiansen, K. Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow. J. Chem. Inf. Model. 2013, 53, 923-937.
9. Day, C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet. Med. 1999, 16, 179-192.
10. Moya, M.; Gómez-Lechón, M.J.; Castell, J.V.; Jover, R. Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem. Biol. Interact. 2010, 184, 376-387.
11. Pan, H.J.; Lin, Y.; Chen, Y.E.; Vance, D.E.; Leiter, E.H. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: Relation to dysregulated phosphatidylcholine metabolism. Vascul. Pharmacol. 2006, 45, 65-71.
12. Bruning, J.B.; Chalmers, M.J.; Prasad, S.; Busby, S.A.; Kamenecka, T.M.; He, Y.; Nettles, K.W.; Griffin, P.R. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 2007, 15, 1258-1271.
13. Guasch, L.; Sala, E.; Castell-Auví, A.; Cedó, L.; Liedl, K.R.; Wolber, G.; Muehlbacher, M.; Mulero, M.; Pinent, M.; Ardévol, A.; et al. Identification of PPARgamma partial agonists of natural origin (I): Development of a virtual screening procedure and in vitro validation. PLoS One 2012, 7, e50816.
14. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.
15. Waku, T.; Shiraki, T.; Oyama, T.; Maebara, K.; Nakamori, R.; Morikawa, K. The nuclear receptor PPARγ individually responds to serotonin-and fatty acid-metabolites. EMBO J. 2010, 29, 3395-3407.
16. Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K.; Schwabe, J.W. Structural basis for the activation of PPARγ by oxidized fatty acids. Nat. Struct. Mol. Biol. 2008, 15, 924-931.
17. Li, Y.; Zhang, J.; Schopfer, F.J.; Martynowski, D. Garcia-Barrio, M.T.; Kovach, A.; Suino-Powell, K.; Baker, P.R.; Freeman, B.A.; Chen, Y.E.; et al. Molecular recognition of nitrated fatty acids by PPARγ. Nat. Struct. Mol. Biol. 2008, 15, 865-867.
18. Gampe, R.T., Jr.; Montana, V.G.; Lambert, M.H.; Miller, A.B.; Bledsoe, R.K.; Milburn, M.V.; Kliewer, S.A.; Willson, T.M.; Xu, H.E. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell. 2000, 5, 545-555.
19. Liberato, M.V.; Nascimento, A.S.; Ayers, S.D.; Lin, J.Z.; Cvoro, A.; Silveira, R.L.; Martínez, L.; Souza, P.C.; Saidemberg, D.; Deng, T.; et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR)γ activators and pan-PPAR partial agonists. PLoS One 2012, 7, e36297.
20. Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T.P.; Rastinejad, F. Structure of the intact PPAR-γ-RXR-nuclear receptor complex on DNA. Nature 2008, 456, 350-356.
21. Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395, 137-143.
22. Li, Y.; Kovach, A.; Suino-Powell, K.; Martynowski, D.; Xu, H.E. Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1α. J. Biol. Chem. 2008, 283, 19132-19139.
23. Li, Y.; Choi, M.; Suino, K.; Kovach, A.; Daugherty, J.; Kliewer, S.A.; Xu, H.E. Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc. Natl. Acad. Sci. USA 2005, 102, 9505-9510.
24. Pencheva, T.; Jereva, D.; Miteva, M.; Pajeva, I. Post-docking optimization and analysis of protein-ligand interactions of estrogen receptor alpha using ammos software. Curr. Comput. Aided Drug Des. 2012, 9, 83-94.
25. Xu, H.E.; Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; Gampe, R.T., Jr.; McKee, D.D.; et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 2001, 98, 13919-13924.
26. Ohashi, M.; Oyama, T.; Nakagome, I.; Satoh, M.; Nishio, Y.; Nobusada, H.; Hirono, S.; Morikawa, K.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: Discovery of reversed stereochemistry-activity relationship. J. Med. Chem. 2011, 54, 331-341.
27. Zhang, H.; Ryono, D.E.; Devasthale, P.; Wang, W.; O'Malley, K.; Farrelly, D.; Gu, L.; Harrity, T.; Cap, M.; Chu, C.; et al. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. Bioorg. Med. Chem. Lett. 2009, 19, 1451-1456.
28. Casimiro-Garcia, A.; Bigge, C.F.; Davis, J.A.; Padalino, T.; Pulaski, J.; Ohren, J.F.; McConnell, P.; Kane, C.D.; Royer, L.J.; Stevens, K.A.; et al. Synthesis and evaluation of novel α-heteroarylphenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. Bioorg. Med Chem. 2009, 17, 7113-7125.
29. Cronet, P.; Petersen, J.F.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E.L.; Bamberg, K. Structure of the PPARalpha and-gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
30. Bénardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Boehringer, M.; Grether, U.; Hilpert, H.; Kuhn, B.; Märki, H.P.; Meyer, M.; et al. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorg. Med. Chem. Lett. 2009, 19, 2468-2473.
31. Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J.I.; Hashimoto, Y.; Miyachi, H.; Morikawa, K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta. Crystallogr. D Biol. Crystallogr. 2009, 65, 786-795.
32. Lin, C.H.; Peng, Y.H.; Coumar, M.S.; Chittimalla, S.K.; Liao, C.C.; Lyn, P.C.; Huang, C.C.; Lien, T.W.; Lin, W.H.; Hsu, J.T.; et al. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. J. Med. Chem. 2009, 52, 2618-2622.
33. Kuwabara, N.; Oyama, T.; Tomioka, D.; Ohashi, M.; Yanagisawa, J.; Shimizu, T.; Miyachi, H. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: Phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. J. Med. Chem. 2012, 55, 893-902.
34. Mahindroo, N.; Wang, C.C.; Liao, C.C.; Huang, C.F.; Lu, I.L.; Lien, T.W.; Peng, Y.H.; Huang, W.J.; Lin, Y.T.; Hsu, M.C.; et al. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: Design, synthesis, structural biology, and molecular docking studies. J. Med. Chem. 2006, 49, 1212-1216.
35. Casimiro-Garcia, A.; Bigge, C.F.; Davis, J.A.; Padalino, T.; Pulaski, J.; Ohren, J.F.; McConnell, P.; Kane, C.D.; Royer, L.J.; Stevens, K.A.; et al. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies. Bioorg. Med. Chem. 2008, 16, 4883-4907.
36. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P.S.; Mogensen, J.P.; Wassermann, K.; Brand, C.L.; Sturis, J.; Wöldike, H.F.; Fleckner, J.; et al. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: Dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 2002, 45, 789-804.
37. Grether, U.; Bénardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Hilpert, H.; Kuhn, B.; Märki, H.P.; Meyer, M.; Mohr, P.; et al. Design and biological evaluation of novel, balanced dual PPARα/γ agonists. ChemMedChem 2009, 4, 951-956.
38. Mahindroo, N.; Peng, Y.H.; Lin, C.H.; Tan, U.K.; Prakash, E.; Lien, T.W.; Lu, I.L.; Lee, H.J.; Hsu, J.T.; Chen, X.; et al. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. J. Med. Chem. 2006, 49, 6421-6424.
39. Mahindroo, N.; Huang, C.F.; Peng, Y.H.; Wang, C.C.; Liao, C.C.; Lien, T.W.; Chittimalla, S.K.; Huang, W.J.; Chai, C.H.; Prakash, E.; et al. Novel indole-based peroxisome proliferator-activated receptor agonists: Design, SAR, structural biology, and biological activities. J. Med. Chem. 2005, 48, 8194-8208.
40. Mueller, J.J.; Schupp, M.; Unger, T.; Kintscher, U.; Heinemann, U. Binding Diversity of Pioglitazone by Peroxisome Proliferator-Activated Receptor-Gamma. Unpublished work, 2011.
41. Ebdrup, S.; Pettersson, I.; Rasmussen, H.B.; Deussen, H.J.; Frost Jensen, A.; Mortensen, S.B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. J. Med. Chem. 2003, 46, 1306-1317.
42. Kuhn, B.; Hilpert, H.; Benz, J.; Binggeli, A.; Grether, U.; Humm, R.; Märki, H.P.; Meyer, M.; Mohr, P. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Bioorg. Med. Chem. Lett. 2006, 16, 4016-4020.
43. MOE (Molecular Operating Environment) Version 2013.08; Chemical Computing Group Inc.: Montreal, QC, Canada, 2013.
44. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012, 40, D1100-D1107.